Literature DB >> 23994633

Proteasome inhibitor MG132 enhances TRAIL-induced apoptosis and inhibits invasion of human osteosarcoma OS732 cells.

Xiucheng Li1, Tao Huang, Guangjian Jiang, Weihua Gong, Hao Qian, Chunping Zou.   

Abstract

MG132 as a proteasome inhibitor could induce apoptosis in various cancer cells. This study aimed to discuss the effect of proteasome inhibitor MG132 on the TRAIL-induced apoptosis of human osteosarcoma OS732 cells. MG132 and TRAIL were applied on OS732 cells respectively or jointly. Cell survival rates, changes of cellular shape, cell apoptosis and cell invasion were analyzed, respectively, by 3-(4,5)-dimethylthiahiazo(-z-y1)-2,5-di-phenytetrazoliumromide (MTT) assay, inverted phase contrast microscope, flow cytometry, and transwell invasion chamber methods. The protein levels of DR5, caspase-3, caspase-8, p27(kip1) and MMP-9 were measured by Western blot analysis. The results indicated that combination of MG132 and TRAIL had the effect of up-regulating expression of DR5, caspase-3, caspase-8 and p27(kip1), down-regulating expression of MMP-9 and inducing apoptosis as well as suppressing the ability of invasion of OS732 cells. The survival rate of combined application of 10 μM MG132 and 100 ng/ml TRAIL on OS732 cells was significantly lower than that of the individual application (p<0.01). Changes of cellular shape and apoptotic rates also indicated the apoptosis-inducing effect of combined application was much stronger than that of individual application. Cell cycle analysis showed combination of MG132 and TRAIL mostly caused OS732 cells arrested at G2-M-phase. The invasion ability of OS732 cells was restrained significantly in the combined group compared with the individual group and control group.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Apoptosis; Invasion; MG132; Osteosarcoma; TRAIL

Mesh:

Substances:

Year:  2013        PMID: 23994633     DOI: 10.1016/j.bbrc.2013.08.066

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  8 in total

Review 1.  Targeting the unfolded protein response in head and neck and oral cavity cancers.

Authors:  Daniel W Cole; Peter F Svider; Kerolos G Shenouda; Paul B Lee; Nicholas G Yoo; Thomas M McLeod; Sean A Mutchnick; George H Yoo; Randal J Kaufman; Michael U Callaghan; Andrew M Fribley
Journal:  Exp Cell Res       Date:  2019-05-07       Impact factor: 3.905

2.  Functional role of lysine 12 in Leishmania major AQP1.

Authors:  Mansi Sharma; Goutam Mandal; Srotoswati Mandal; Hiranmoy Bhattacharjee; Rita Mukhopadhyay
Journal:  Mol Biochem Parasitol       Date:  2015-08-07       Impact factor: 1.759

3.  Combined application of Embelin and tumor necrosis factor-related apoptosis-inducing ligand inhibits proliferation and invasion in osteosarcoma cells via caspase-induced apoptosis.

Authors:  Hao Qian; Yao Chen; Tao Huang; Tiemin Liu; Xiucheng Li; Guangjian Jiang; Wei Zhang; Shuo Cheng; Pengcheng Li
Journal:  Oncol Lett       Date:  2018-03-08       Impact factor: 2.967

Review 4.  Proteasome Inhibitors and Their Potential Applicability in Osteosarcoma Treatment.

Authors:  Cassidy M Van Stiphout; Anita K Luu; Alicia M Viloria-Petit
Journal:  Cancers (Basel)       Date:  2022-09-20       Impact factor: 6.575

5.  Proteasome inhibitor MG132 inhibits the proliferation and promotes the cisplatin-induced apoptosis of human esophageal squamous cell carcinoma cells.

Authors:  Lifeng Dang; Fengbiao Wen; Yang Yang; Donglei Liu; Kai Wu; Yu Qi; Xiangnan Li; Jia Zhao; Dengyan Zhu; Chunyang Zhang; Song Zhao
Journal:  Int J Mol Med       Date:  2014-02-27       Impact factor: 4.101

6.  Identification of Synergistic, Clinically Achievable, Combination Therapies for Osteosarcoma.

Authors:  Diana Yu; Elliot Kahen; Christopher L Cubitt; Jeremy McGuire; Jenny Kreahling; Jae Lee; Soner Altiok; Conor C Lynch; Daniel M Sullivan; Damon R Reed
Journal:  Sci Rep       Date:  2015-11-25       Impact factor: 4.379

Review 7.  Cell apoptosis, autophagy and necroptosis in osteosarcoma treatment.

Authors:  Jing Li; Zuozhang Yang; Yi Li; Junfeng Xia; Dongqi Li; Huiling Li; Mingyan Ren; Yedan Liao; Shunling Yu; Yanjin Chen; Yihao Yang; Ya Zhang
Journal:  Oncotarget       Date:  2016-07-12

8.  Lipid Nanoparticles Decorated with TNF-Related Aptosis-Inducing Ligand (TRAIL) Are More Cytotoxic than Soluble Recombinant TRAIL in Sarcoma.

Authors:  Ana Gallego-Lleyda; Diego De Miguel; Alberto Anel; Luis Martinez-Lostao
Journal:  Int J Mol Sci       Date:  2018-05-13       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.